Clinical trials: Koch's Disease
Pulmonary Tuberculosis
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
The UNITE4TB consortium is a group of universities and pharmaceutical companies funded by the European Union. This consortium are carrying out a trial to find better and faster ways to treat tuberculosis (TB).
- Trial name
- PARADIGM4TB (NCT06114628)
- Testing
- Ganfeborole, BTZ-043, Bedaquiline (B)
- Where
- 11 sites in Moldova, South Africa and 3 more
- Volunteers
- 2,500 people
- Sponsor
- University College, London
Multidrug Resistant Tuberculosis
Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
The purpose of this study is to monitor and evaluate the safety and effectiveness of Delamanid in combination with an optimal background regimen (OBR) of anti-TB drugs for treatment of MDR-TB.
- Trial name
- NCT04421495
- Testing
- Delamanid
- Where
- 25 sites in China
- Volunteers
- 608 people
- Sponsor
- Beijing Chest Hospital
Tuberculosis, Pediatric Infectious Disease
Evaluation of Xpert MTB/RIF Ultra in Stools and Urine to Improve Tuberculosis Diagnosis in Children
Tuberculosis (TB) diagnosis in children is challenging in low and middle-income countries where access to TB culture and X-ray is limited. More than half cases of childhood TB remain undiagnosed every year.
- Trial name
- NCT06239337
- Testing
- Xpert MTB/RIF Ultra in stools and urine
- Where
- 2 sites in Guinea-Bissau, South Sudan
- Volunteers
- 563 people
- Sponsor
- Medecins Sans Frontieres, Spain
Tuberculosis
Pharmacokinetic and Therapeutic Adaptation of Linezolid in the Treatment of Multi-Resistant Tuberculosis
Linezolid, primary treatment for MDR-TB combination therapy anti. Until it is the dose of 600 mg x1 / day, rather sensible for most patients is more, which was unanimous.
- Trial name
- LINEZOLIDE (NCT02778828)
- Testing
- Linezolid
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Tuberculosis
A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB
This was a double-blind, randomized, placebo-controlled dose-escalation study in adults recently treated for pulmonary TB. The dose of AERAS-402 increased in successive dose groups. Enrollment into a dose group was sequential.
- Trial name
- C-010-402 (NCT02414828)
- Testing
- AERAS-402 3 x 10^8 vp, AERAS-402 3 x 10^9 vp, AERAS-402 3 x 10^10 vp
- Where
- South Africa
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Aeras
Tuberculosis; Uveitis (Manifestation), Anti-Tuberculous Drug Reaction
Proportion of Clinical Improvement & Type 1 Interferon (IFN) Score Changes in Idiopathic Uveitis Patients With Interferon Gamma Release Assay (IGRA) Positive
The aim of this study is to determine the proportion of clinical improvement, the score changing of type 1 interferon selected gene expression, and analysis of transcriptomics profiling in patients with idiopathic uveitis…
- Conditions
- Tuberculosis; Uveitis (Manifestation), Anti-Tuberculous Drug Reaction, Tuberculous Uveitis
- Trial name
- NCT04088019
- Testing
- Fixed drug combination (FDC) of ATT and Oral steroid
- Where
- Indonesia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fakultas Kedokteran Universitas Indonesia
Tuberculosis, Gastric Cancer
Volatiles in Breath and Headspace Analysis - Diagnostic Markers
Detection of Volatile Organic Compounds (VOC) directly from tissue by headspace analysis (skin, surgery material, other tissue) and exhaled breath is feasible using affordable user-friendly novel nano-chemo sensors that can…
- Conditions
- Tuberculosis, Gastric Cancer, Peptic Ulcer, Atrophic Gastritis
- Trial name
- Volatolome (NCT03228095)
- Testing
- VOC detection in breath and in skin headspace, Breath sampling, Upper endoscopy with biopsies
- Where
- Latvia
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of Latvia
Tuberculosis
Siemens VOC TB Pilot Study
Tuberculosis is a bacterial infection causing 1.1 million deaths annually worldwide. Diagnosis of the disease is often time consuming or challenging.
- Trial name
- NCT01748357
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Research Center Borstel
Latent Tuberculosis Infection
Latent Tuberculosis Infection Screening Using QuantiFERON at Pre-Employment Assessment in Hospital Workers CHu Nice
This retrospective observational single-center study aims to evaluate the medical and occupational relevance of systematic screening for latent tuberculosis infection using QuantiFERON-TB Gold Plus during pre-employment…
- Trial name
- NCT07608601
- Testing
- QuantiFERON-TB Gold Plus
- Where
- France
- Volunteers
- 1,185 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Tuberculosis, Post-Tuberculous Pleural Fibrosis
Endurance Training in Patients With Post-TB Lung Disease
To determine the effects of endurance training on functional capacity and QOL(Quality of life) in patients with post-TB (tuberculosis) lung disease. Post-tuberculosis lung disease is a major health concern nowadays.
- Conditions
- Tuberculosis, Post-Tuberculous Pleural Fibrosis, Post-Tuberculous Bronchiectasis
- Trial name
- NCT06047795
- Testing
- Experimental, Control
- Where
- Pakistan
- Volunteers
- 36 people
- Sponsor
- Riphah International University
Tuberculosis, Multidrug-Resistant, Infection, Bacterial
Evaluating Newly Approved Drugs for Multidrug-resistant TB
endTB Clinical Trial a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of five new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB).
- Conditions
- Tuberculosis, Multidrug-Resistant, Infection, Bacterial, Pulmonary Tuberculoses
- Trial name
- endTB (NCT02754765)
- Testing
- Bedaquiline, Delamanid, Clofazimine
- Where
- 12 sites in Georgia, India and 5 more
- Volunteers
- 754 people
- Sponsor
- Médecins Sans Frontières, France
Mediastinal Lymphadenopathy, Lung Cancer
Mediastinal EBUS Cryobiopsy Study In Sweden
This study is a prospective observational non-randomized clinical trial where all the participitants undergo the same procedure and every participitant's samples are compared to each other.
- Conditions
- Mediastinal Lymphadenopathy, Lung Cancer, Sarcoidosis, Lymphoma
- Trial name
- MECRIS (NCT06347939)
- Testing
- Mediastinal lymph nodes cryobiopsies
- Where
- 2 sites in Sweden
- Volunteers
- 200 people
- Sponsor
- Region Skane
HIV Infections, Tuberculosis
Observational Study of Specificity of Mycobacterium Tuberculosis Screening and Diagnostics in HIV-Infected Individuals
An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with projected rates of requirement for ARV therapy extending to more than 10 million in sub-Saharan…
- Trial name
- NCT00865826
- Testing
- Standardized diagnostic evaluation
- Where
- 13 sites in Botswana, Brazil and 5 more
- Volunteers
- 801 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Tuberculosis
Development of a Clinical-epidemiological Score Predictive of Tuberculosis.
Despite being a curable and preventable disease, tuberculosis still represents a major global health problem. It is estimated that 10.8 million people contracted tuberculosis in 2023, with an incidence of 134 per 100,000…
- Trial name
- SCORE-TB (NCT07485868)
- Testing
- Development and validation of a clinical-epidemiological predictive score for the diagnosis of pulmonary tuberculosis
- Volunteers
- 686 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Tuberculosis
A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A
The purpose of this study is to evaluate the BCG 'challenge' model a four-arm study design has been chosen. Twelve subjects will be recruited into each arm of the study.
- Trial name
- NCT01194180
- Testing
- BCG: 100 microlitres ~ 2-8 x 105 pfu, MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Pulmonary TB
A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis
This trial will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of multiple oral doses of OPC-167832 in participants with uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis (TB).
- Trial name
- NCT03678688
- Testing
- 10 mg OPC-167832, 30 mg OPC-167832, 90 mg OPC-167832
- Where
- 3 sites in South Africa
- Volunteers
- 122 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, Diagnoses Disease
TB-CAPT CORE Truenat Trial
A cluster randomized controlled trial to evaluate the effect of placing Truenat platform/TB assays at primary health care clinics combined with rapid communication of results on time to treatment initiation of microbiologically…
- Trial name
- NCT04568954
- Testing
- Truenat TB platform/TB assays
- Where
- 4 sites in Mozambique, Tanzania
- Volunteers
- 3,987 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Tuberculosis
Safety and Immunogenicity of Nyaditum Resae® Probiotic to Protect From Tuberculosis
This is a double-blind, masked, compared with placebo clinical trial in healthy volunteers with or without tuberculosis infection.
- Trial name
- NCT02076139
- Testing
- Nyaditum resae® 10e4, Nyaditum resae® 10e5, Distilled water
- Where
- Spain
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Manresana de Micobacteriologia, SL
Tuberculosis, HIV Infections
Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
HIV-infected people have an increased risk of developing active tuberculosis (TB). At the time the study was designed, the standard course of treatment for TB was 6 to 9 months of isoniazid (INH).This study compared the safety…
- Trial name
- NCT01404312
- Testing
- Rifapentine (RPT), Isoniazid (INH), Pyridoxine (Vitamin B6)
- Where
- 45 sites in United States, Botswana and 8 more
- Volunteers
- 3,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pulmonary Tuberculosis
TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
This Phase 2, multicenter, open-label clinical trial evaluated the antimicrobial activity and safety of rifapentine-containing regimens during the intensive phase of pulmonary tuberculosis treatment.
- Trial name
- NCT00694629
- Testing
- rifapentine, rifapentine 10 mg/kg, rifapentine 15 mg/kg
- Where
- 29 sites in United States, Brazil and 4 more
- Volunteers
- 334 people
- Sponsor
- Centers for Disease Control and Prevention
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.